Pharmaceuticals Raw Materials Bulk sulfadimoxine Powder

CAS:2447-57-6

MF:C12H14N4O4S

MW:310.33

EINECS:219-504-9    

Specification: 99% min sulfadimoxine Powder

Sample:sulfadimoxine Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

sulfadimoxine Powder Usage and Synthesis.

Weekly Sulfanilamide, English name sulfadoxine Alias Weekly Sulfanilamide, Sulfadoxine, Sulfadoxine-o-dimethoxypyrimidine. It is a white or off-white crystalline powder, which is mainly used for bronchitis, pneumonia, bacillary dysentery, urinary tract infections, skin and soft tissue infections and prevention of rheumatic fever. It has significant antibacterial effect on staphylococcus, pneumococcus, coli, salmonella, etc. It also has inhibitory effect on plasmodium. It is effective for one week after one dose, with low toxicity and few side effects.

Uses and functions of sulfadimoxine.

Sulfanilamide is generally used in the treatment of inflammatory diseases, such as upper respiratory tract infections, tonsillitis, dysentery, enteritis, skin infections, etc. It can also be used in conjunction with other drugs for the treatment of tuberculosis, lymphoma and other diseases.

Ultra-long-acting sulfonamides are used to treat meningitis and urinary tract infections.

Pharmacological Effect of sulfadimoxine.

Sulfanilamide is a systemic long-acting sulfonamide, a broad-spectrum antibacterial agent. The antibacterial mechanism of sulfadoxine is similar to that of other sulfonamides, which can compete with amino benzoic acid (PABA) to act on dihydrofolate synthetase in the bacterial body, thus preventing PABA from synthesising the tetrahydrofolate required by bacteria as raw material, and then inhibiting the synthesis of bacterial proteins and acting as an antibacterial agent.

Preparation of  Bulk sulfadimoxine Powder.

(1), causing methyl methoxyacetate and excess diethyl oxalate to react to form methyl 3-methoxy-2-oxosuccinic acid methyl ester, and decarbonylating to obtain methyl 2-methoxy-malonate;

(2), reacting methyl ethyl 2-methoxy-malonate with formamide to form a cyclic compound;

(3), so that the cyclic compound reacts with trichlorophosphorus to form chloride;

(4), condensation reaction;

(5), the methyl oxidation reaction, wherein: controlling the resulting cyclic compound in the form of anhydrous hydroxyl sodium salt in step (2) makes it possible not to use N,N-dimethylaniline as a catalyst in step (3), which makes it possible to reduce the cost as well as to improve the quality of the chloride, and ultimately to improve the quality of the circumscribed sulfonamide.